Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HuMax IL8 - Bristol-Myers Squibb/Genmab

Drug Profile

HuMax IL8 - Bristol-Myers Squibb/Genmab

Alternative Names: anti-IL8 mAb - Bristol-Myers Squibb/Genmab; BMS-986253; HuMax-IL8; HuMax-Inflam; HuMax®-IL8; MDX 018

Latest Information Update: 26 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Medarex
  • Developer Bristol-Myers Squibb; Columbia University; Genmab; Icahn School of Medicine at Mount Sinai; Medarex
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; Liver cancer; Non-small cell lung cancer
  • Phase I/II Prostate cancer; Solid tumours
  • Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis

Most Recent Events

  • 29 May 2020 Efficacy data from the phase I/II MAGIC-8 trial in Prostate cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 16 Apr 2020 Phase-II clinical trials in COVID-2019 infections in cancer patients (Treatment-experienced) in USA (IV) (NCT04347226)
  • 13 Nov 2019 Phase-II clinical trials in Liver cancer (Combination therapy, Neoadjuvant therapy) in USA (Parenteral) (NCT04123379)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top